On top of generating and managing strategic clinical trials in Oncology for many of the most important drugs on the market such as osimertinib, pembrolizumab, pertuzumab, T-DM1, olaparib, niraparib, eribulin, palbociclib, fulvestrant, and radium-223, over the last few years MedSIR has organized large scientific events, bringing together a number of international key opinion leaders in Oncology and Basic Research to discuss cutting edge topics in an environment that promotes proactivity and a dynamic interchange of ideas. Not surprisingly, many ideas for future studies have stemmed from these gatherings. For example, MedSIR will launch its first trials using Immunotherapy (atezolizumab and pembrolizumab) that were developed with ideas stemming from its Immunology Workshop. Additional strategic ideas were generated from other events such as MedSIR’s European Think Tank on Breast Cancer.

For more specific information of these events, we invite you to click on the links below…